Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jules H. Blank"'
Autor:
Robert Hegeman, Dhimant Patel, Leah L. Dietrich, Wei Xu, Anne M. Traynor, KyungMann Kim, Sandeep Saha, Amye J. Tevaarwerk, Mark E. Burkard, Josephine Harter, Kari B. Wisinski, Jules H. Blank
Publikováno v:
Clinical Breast Cancer. 16:256-261
Background Estrogen receptor beta (ERβ) is expressed by 50% to 80% of triple-negative breast cancers (TNBC). Agonism of ERβ has antiproliferative effects in TNBC cells expressing ERβ. This phase 2 study evaluated single-agent high-dose estradiol i
Autor:
Lynn M. Volk, Jules H. Blank, Brad S. Kahl, Anne M. Traynor, Matthias Weiss, KyungMann Kim, Ronald S. Go, Jens C. Eickhoff, Jae Werndli, Rachel Kirby-Slimp, Julie E. Chang, Thomas C. Havighurst
Publikováno v:
British Journal of Haematology. 173:283-291
Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is
Autor:
Arielle Baim, Jules H. Blank, Sandeep Saha, Harish Ahuja, Anne M. Traynor, Timothy S. Fenske, Ryan J. Mattison, Tim Wassenaar, Kyung Mann Kim, Namrata Shah, Patrick Mansky, Rubina Qamar, Chong Zhang, John P. Farnen, Brad S. Kahl, Adedayo A. Onitilo
Publikováno v:
Cancer. 121:3465-3471
BACKGROUND Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B-cell malignancies and affect distinct cellular pathways. Their combination has demonstrated synergy in vitro and in mouse models. METHODS Th
Autor:
Lakeesha Carmichael, Walter L. Longo, Michael S. Huie, Natalie S. Callander, Julie E. Chang, Jules H. Blank, Christopher Peterson, Jae Werndli, David T. Yang, Anne M. Traynor, Brad S. Kahl, KyungMann Kim, Thomas McFarland, Michael Volk
Publikováno v:
Clinical lymphoma, myelomaleukemia. 18(1)
Introduction VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. Patients
Autor:
Peter H. Johnson, Jules H. Blank, Tien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Anne M. Traynor, Harish Ahuja, Jill M. Kolesar, Mary E. Wims, Michael S. Huie, Emily Robinson, Hilary R. Hernan, Ron J. Kirschling, Kurt R. Oettel, Martha M. Larson
Publikováno v:
Investigational New Drugs. 32:195-199
Introduction The primary objective of this phase II trial was to evaluate the efficacy and tolerability of vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer (NSCLC) patients. Methods Eligibility criteria included
Autor:
Jules H. Blank, Sangbum Choi, Michael S. Huie, Thomas McFarland, Leslie A. Gilbert, Jae Werndli, Brad S. Kahl, Walter L. Longo, Julie E. Chang, Michael Volk, KyungMann Kim, Natalie S. Callander, Eric S. Rogers, Christopher Peterson, Jens C. Eickhoff, David T. Yang
Publikováno v:
British Journal of Haematology. 155:190-197
Summary Intensive chemotherapy regimens are not feasible in many adults with mantle cell lymphoma (MCL). We sought to build upon our previous experience with a non-intensive regimen, modified R-hyperCVAD chemotherapy (rituximab, cyclophosphamide, vin
Autor:
Brad S. Kahl, Wayne A. Bottner, Vaishalee P. Kenkre, Jens C. Eickhoff, Jules H. Blank, Walter L Long, Jae Werndli, Hamied Rezazedeh, Thomas McFarland, Howard H. Bailey
Publikováno v:
Leukemia & Lymphoma. :1-6
Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3-5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our i
Autor:
Mary Jane Staab, Harish Ahuja, Jules H. Blank, Rebecca Marnocha, Alcee Jumonville, Dottie Horvath, Dona Alberti, Jens C. Eickhoff, Jane Straus, Michael Eastman, Michael Glode, Douglas G. McNeel, Glenn Liu, Steven Attia, George Wilding, Daniel H. Shevrin
Publikováno v:
Clinical Cancer Research. 14:2437-2443
Purpose: Docetaxel is standard of care for androgen-independent prostate cancer (AIPC). Doxercalciferol (1α-hydroxyvitamin D2) had modest activity in phase I/II trials. Preclinical data support combining vitamin D analogues with docetaxel to treat A
Autor:
Timothy S, Fenske, Namrata M, Shah, Kyung Mann, Kim, Sandeep, Saha, Chong, Zhang, Arielle E, Baim, John P, Farnen, Adedayo A, Onitilo, Jules H, Blank, Harish, Ahuja, Tim, Wassenaar, Rubina, Qamar, Patrick, Mansky, Anne M, Traynor, Ryan J, Mattison, Brad S, Kahl
Publikováno v:
Cancer. 121(19)
Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B-cell malignancies and affect distinct cellular pathways. Their combination has demonstrated synergy in vitro and in mouse models.The authors conducted
Autor:
Jae Werndli, Michael S. Huie, Michael Volk, Walter L. Longo, David T. Yang, Anne M. Traynor, KyungMann Kim, Thomas McFarland, Brad S. Kahl, Natalie S. Callander, Christopher Peterson, Jules H. Blank, Julie E. Chang, Lakeesha Carmichael
Publikováno v:
Blood. 128:149-149
Introduction: There remains no clear standard first-line therapy for MCL. VcR-CVAD is a novel, intermediate-intensity chemoimmunotherapy regimen which incorporates bortezomib into modified hyper-CVAD chemotherapy. We hypothesized that the addition of